Govt Invites Proposals Under Rs 50 Billion Pharma-MedTech Scheme

03 Oct 2025 CW Team

Revised guidelines have been issued to enhance the scheme’s effectiveness. For early-stage projects, MSMEs and startups may seek support of up to Rs 50 million for projects costing up to Rs 900 million. For later-stage projects, companies, MSMEs and startups may apply for assistance up to Rs 10 billion for projects valued at Rs 28.5 billion. Early-stage projects will receive 100 per cent support up to Rs 10 million, and 50 per cent beyond that, capped at Rs 50 million. Later-stage projects will receive 35 per cent support, capped at Rs 10 billion.

In Strategic Priority Innovation (SPI) areas—such as rare diseases, antimicrobial resistance, vaccine-preventable illnesses, tropical vector-borne diseases and pandemic pathogens—later-stage projects may receive 50 per cent assistance, capped at Rs 10 billion.

The scheme also incentivises industry, MSMEs and startups to collaborate with leading academic and government research institutions, offering preferential selection for up to nine early- and late-stage projects involving significant partnerships. Assistance may also be used for in-licensing research outputs from such institutions, linking academic strengths with industry’s capacity to scale technologies to market.

Institutional enablers will be strengthened through Centres of Excellence at seven NIPERs, acting as advanced research hubs. The NIPER Academia-Industry Coordination Committee will further enhance collaboration, while a digital Pharma-MedTech Innovation Exchange will connect innovators with investors, mentors and global opportunities.

The fully digital application process opened on 1 October 2025 via the PRIP portal. By attracting both domestic and international participation, the scheme aims to accelerate affordable, high-quality healthcare solutions, strengthen India’s public health resilience and position the country as a global leader in pharmaceutical and MedTech innovation.

The Department of Pharmaceuticals has opened applications for research and innovation projects under its Promotion of Research and Innovation in Pharma-MedTech Sector (PRIP) scheme, a landmark initiative aimed at transforming India into a globally competitive, innovation-led hub. With an approved outlay of Rs 50 billion, the scheme is expected to support around 300 projects, catalysing total R&D investment of about Rs 110 billion in new medicines, complex generics, biosimilars and novel medical devices.Revised guidelines have been issued to enhance the scheme’s effectiveness. For early-stage projects, MSMEs and startups may seek support of up to Rs 50 million for projects costing up to Rs 900 million. For later-stage projects, companies, MSMEs and startups may apply for assistance up to Rs 10 billion for projects valued at Rs 28.5 billion. Early-stage projects will receive 100 per cent support up to Rs 10 million, and 50 per cent beyond that, capped at Rs 50 million. Later-stage projects will receive 35 per cent support, capped at Rs 10 billion.In Strategic Priority Innovation (SPI) areas—such as rare diseases, antimicrobial resistance, vaccine-preventable illnesses, tropical vector-borne diseases and pandemic pathogens—later-stage projects may receive 50 per cent assistance, capped at Rs 10 billion.The scheme also incentivises industry, MSMEs and startups to collaborate with leading academic and government research institutions, offering preferential selection for up to nine early- and late-stage projects involving significant partnerships. Assistance may also be used for in-licensing research outputs from such institutions, linking academic strengths with industry’s capacity to scale technologies to market.Institutional enablers will be strengthened through Centres of Excellence at seven NIPERs, acting as advanced research hubs. The NIPER Academia-Industry Coordination Committee will further enhance collaboration, while a digital Pharma-MedTech Innovation Exchange will connect innovators with investors, mentors and global opportunities.The fully digital application process opened on 1 October 2025 via the PRIP portal. By attracting both domestic and international participation, the scheme aims to accelerate affordable, high-quality healthcare solutions, strengthen India’s public health resilience and position the country as a global leader in pharmaceutical and MedTech innovation.

Equipment

09 Jan 2026

BKT Partners All Teams in India’s Women’s T20 League

Balkrishna Industries (BKT), a global leader in the off-highway tyre market, announced its association as the Official Tyre Partner for all five teams competing in India’s premier women’s T20 championship – Mumbai Indians, Royal Challengers Bangalore, Delhi Capitals, Gujarat Giants, and UP Warriorz – for the upcoming season. This move reinforces BKT’s commitment to using sport as a platform for inclusion, opportunity, and long-term development.These partnerships reflect BKT’s belief in the transformative power of sport, particularly in advancing women’s participation and creating..

Infrastructure Energy

09 Jan 2026

Rajesh Power Secures 65 MW BESS Project in Gujarat

Rajesh Power Services has recently secured a 65 MW / 130 MWh standalone Battery Energy Storage System (BESS) project in Gujarat, marking its entry into utility-scale energy storage. The company received a Letter of Intent from Gujarat Urja Vikas Nigam for the project, which will be developed at Virpore under a tariff-based competitive bidding mechanism supported by Viability Gap Funding through the Power System Development Fund.The project is expected to be executed within 18 months from the signing of the Battery Energy Storage Purchase Agreement. With the ability to supply 65 MW of power for..

Infrastructure Energy

09 Jan 2026

ONGC Forms JV with MOL for Ethane Shipping Operations

Oil and Natural Gas Corporation (Oil and Natural Gas Corporation) has recently entered the ethane shipping segment through joint venture agreements with M/s Mitsui O.S.K. Lines Ltd (Mitsui O.S.K. Lines), Japan. The agreements involve equity participation in two joint venture entities—Bharat Ethane One IFSC Private Limited and Bharat Ethane Two IFSC Private Limited—registered at GIFT City, Gandhinagar.Under the arrangement, ONGC will subscribe to 2,00,000 equity shares of Rs 100 each in both entities, resulting in a 50 per cent equity holding in each joint venture, with the remaining stake ..